Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

Q1 2024 Earnings Call Transcript May 4, 2024 Ascendis Pharma A/S isn’t one of the 30 most popular stocks among hedge funds at ...

These factors, combined with the drug’s potential to be a best-in-class therapeutic agent for both achondroplasia (ACH) and hypochondroplasia (HCH), due to its high selectivity for FGFR3 over other ...

The new data presented at the Pediatric Endocrine Society (PES) Annual Meeting regarding the use of Voxzogo for various genetic forms of short stature is promising, indicating a potential for label ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

The recent label expansion of Voxzogo in the United States and Europe for use in infants with achondroplasia will likely lead ...

Meryl - who has achondroplasia which causes dwarfism - was nominated for a Scottish BAFTA for her stint on the reality show. Speaking to OK! Magazine, she revealed: "I quit my job back in December. I ...

The recent label expansion of Voxzogo in the United States and Europe for use in infants with achondroplasia will likely lead to a further boost in the drug’s sales. Its other drugs, like Vimizim and ...

Ascendis Pharma's approved drug, Skytrofa, has shown strong sales and has the potential to be a blockbuster. Read why I'm ...